TOULOUSE, France–(BUSINESS WIRE)–Vexim, the Med-Tech specialist in the minimally invasive, anatomical treatment of vertebral compression fractures, today announced that it has obtained the registration certificate for SpineJack in India. The company will market the SpineJack in India as soon it receives the import license from the Indian authorities.
“This registration certificate shows, once again, SpineJack’s conformity to the requirements of the worldwide market. Even if the deployment of SpineJack in Europe is our first priority, and that deployment is progressing with increasing success given the interest that SpineJack is generating in the global market, we will continue to reply favorably to demand for this product coming from other markets. This is the case for India today and this registration certificate, completed by a pending import license, will soon enable Vexim to start commercializing SpineJack in that market thanks to our local distributor,” emphasized Vexim’s President and CEO Bruce de la Grange.
About the standard SpineJack® implant
The SpineJack® is a titanium implant (5 mm in diameter and 25 mm in length) that covers 80% of spinal column fractures (vertebrae TH10 to L5). It is inserted into a patient’s vertebra via a transpedicular, minimally invasive approach (just one or two 5 mm skin incisions). A simple but specialized set of instruments is used to prepare the vertebra for the X-ray-guided insertion of one or two implants, depending on the anatomical configuration of the fracture and the degree of reconstruction required. Once this step has been completed, bone cement is injected into the restored vertebra in order to secure the vertebral structure and relieve the patient’s pain. A trained surgeon needs only 25 to 35 minutes to complete the whole procedure. The patient can expect a very significant reduction in pain immediately after the operation and will generally be discharged from hospital 24 hours later.
Toulouse-based Vexim was founded in February 2006 as a Teknimed spin-off by the well-known entrepreneur Jacques Essinger and the leading European private equity firm Truffle Capital. Vexim is a Med-Tech company that specializes in minimally invasive solutions for the treatment of vertebral fractures. The company was also subsequently financed by Banexi Ventures in September 2006 and received financial support from Oséo (the French state innovation agency) in 2009. Vexim is developing the SpineJack® system for anatomically optimal restorative surgery of vertebral fractures. In July 2009, the company signed an exclusive agreement with Stryker EMEA for distribution of the SpineJack® in Germany, the UK, Austria and Ireland. SpineJack® is CE marked and was first commercialized in mid-2010. The company currently has 27 employees. For more information, visit the company website at www.vexim.fr.